111 related articles for article (PubMed ID: 26609837)
1. Characterization of Self-Assembled Monolayers of Peptide Mimotopes of CD20 Antigen and Their Binding with Rituximab.
Leo N; Shang Y; Yu JJ; Zeng X
Langmuir; 2015 Dec; 31(51):13764-72. PubMed ID: 26609837
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of the B-cell marker CD20.
Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
[TBL] [Abstract][Full Text] [Related]
3. Ionic Strength, Surface Charge, and Packing Density Effects on the Properties of Peptide Self-Assembled Monolayers.
Leo N; Liu J; Archbold I; Tang Y; Zeng X
Langmuir; 2017 Feb; 33(8):2050-2058. PubMed ID: 28135097
[TBL] [Abstract][Full Text] [Related]
4. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line.
Abdollahpour-Alitappeh M; Hashemi Karouei SM; Lotfinia M; Amanzadeh A; Habibi-Anbouhi M
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1-8. PubMed ID: 29523024
[TBL] [Abstract][Full Text] [Related]
5. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes.
Perosa F; Favoino E; Vicenti C; Guarnera A; Racanelli V; De Pinto V; Dammacco F
J Immunol; 2009 Jan; 182(1):416-23. PubMed ID: 19109173
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.
Li H; Zhang G; Jiang C; Zhang F; Ke C; Zhao H; Sun Y; Zhao M; Chen D; Zhu X; Zhang L; Li B; Dai J; Li W
Oncotarget; 2015 Sep; 6(27):24192-204. PubMed ID: 26284588
[TBL] [Abstract][Full Text] [Related]
7. Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
J Mol Recognit; 2013 Sep; 26(9):432-8. PubMed ID: 23836471
[TBL] [Abstract][Full Text] [Related]
8. CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases.
Perosa F; Favoino E; Caragnano MA; Dammacco F
Ann N Y Acad Sci; 2005 Jun; 1051():672-83. PubMed ID: 16127008
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.
Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Hou S; Guo Y; Ding J
Mol Immunol; 2008 May; 45(10):2861-8. PubMed ID: 18346788
[TBL] [Abstract][Full Text] [Related]
10. The epitope recognized by rituximab.
Binder M; Otto F; Mertelsmann R; Veelken H; Trepel M
Blood; 2006 Sep; 108(6):1975-8. PubMed ID: 16705086
[TBL] [Abstract][Full Text] [Related]
11. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
12. Assessment of physicochemical properties of rituximab related to its immunomodulatory activity.
Miranda-Hernández MP; López-Morales CA; Ramírez-Ibáñez ND; Piña-Lara N; Pérez NO; Molina-Pérez A; Revilla-Beltri J; Flores-Ortiz LF; Medina-Rivero E
J Immunol Res; 2015; 2015():910763. PubMed ID: 25973441
[TBL] [Abstract][Full Text] [Related]
13. Real time analysis of binding between Rituximab (anti-CD20 antibody) and B lymphoma cells.
Tan L; Lin P; Chisti MM; Rehman A; Zeng X
Anal Chem; 2013 Sep; 85(18):8543-51. PubMed ID: 23926879
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a peptide ELISA for the detection of rituximab in serum.
Blasco H; Lalmanach G; Godat E; Maurel MC; Canepa S; Belghazi M; Paintaud G; Degenne D; Chatelut E; Cartron G; Le Guellec C
J Immunol Methods; 2007 Aug; 325(1-2):127-39. PubMed ID: 17651747
[TBL] [Abstract][Full Text] [Related]
15. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies.
Li M; Yan Z; Han W; Zhang Y
Cell Immunol; 2006 Feb; 239(2):136-43. PubMed ID: 16814270
[TBL] [Abstract][Full Text] [Related]
16. Rational Design of Biobetters with Enhanced Stability.
Courtois F; Schneider CP; Agrawal NJ; Trout BL
J Pharm Sci; 2015 Aug; 104(8):2433-40. PubMed ID: 26096711
[TBL] [Abstract][Full Text] [Related]
17. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab.
Rougé L; Chiang N; Steffek M; Kugel C; Croll TI; Tam C; Estevez A; Arthur CP; Koth CM; Ciferri C; Kraft E; Payandeh J; Nakamura G; Koerber JT; Rohou A
Science; 2020 Mar; 367(6483):1224-1230. PubMed ID: 32079680
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab.
Agez M; Mandon ED; Iwema T; Gianotti R; Limani F; Herter S; Mössner E; Kusznir EA; Huber S; Lauer M; Ringler P; Ferrara C; Klein C; Jawhari A
Sci Rep; 2019 Sep; 9(1):13675. PubMed ID: 31548565
[TBL] [Abstract][Full Text] [Related]
19. Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
Scanning; 2013; 35(1):40-6. PubMed ID: 22890585
[TBL] [Abstract][Full Text] [Related]
20. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
